Farhad Imam
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Mechanistic Insights into Hypoxic Preconditioning using Genetic and Genomic Approaches in Zebrafish
Open Date: 2016-08-01
Close Date: 2021-07-31
Articles (6)
The APOE ε4 genetic variant is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) and is increasingly being implicated in other neurodegenerative diseases. Using the Global Neurodegeneration Proteomics Consortium SomaScan dataset covering 1,346 cerebrospinal fluid (CSF) and 9,924 plasma samples, we used machine learning-based proteome profiling to identify an APOE ε4 proteomic signature shared across individuals with AD, frontotemporal dementia (FTD), Parkinson’s disease dementia (PDD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and nonimpaired controls. This signature was enriched in pro-inflammatory immune and infection pathways as well as immune cells, including monocytes, T cells and natural killer cells. Analysis of the dorsolateral prefrontal cortex proteome for 262 donors from the Accelerating Medicines Partnership for AD UPenn Proteomics Study revealed a consistent APOE ε4 phenotype, independent of neurodegenerative pathology, including amyloid-β tau and gliosis for all diseases, as well as TDP-43 in ALS and FTD cases, and α-synuclein in PD and PDD cases. While systemic proteomic changes were consistent across APOE ε4 carriers, their relationship with clinical and lifestyle factors, such as hypertension and smoking, varied by disease. These findings suggest APOE ε4 confers a systemic biological vulnerability that is necessary but not sufficient for neurodegeneration, emphasizing the need to consider gene–environment interactions. Overall, our study reveals a conserved APOE ε4-associated pro-inflammatory immune signature persistent across the brain, CSF and plasma irrespective of neurodegenerative disease, highlighting a fundamental, disease-independent biological vulnerability to neurodegeneration. This work reframes APOE ε4 as a pleiotropic immune modulator rather than an AD-specific risk gene, providing a foundation for precision biomarker development and early intervention strategies across neurodegenerative diseases.
Year:
2025
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids (‘omics’) offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)—a public–private partnership—established one of the world’s largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer’s Disease Data Initiative’s AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research.
Year:
2025
Year:
2025
Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease, Frontotemporal dementia, and Dementia with Lewy bodies) pose diagnostic challenges due to overlapping pathology and clinical heterogeneity. We leveraged proteomic data from more than 21,000 cerebrospinal fluid and plasma samples to develop and validate explainable, boosting-based multi-disease AI classifiers. The models achieved weighted AUCs in the testing datasets of 0.97 for CSF and 0.88 for plasma, equivalent to traditional biomarkers. The model was validated with neuropathological and clinical data, confirming robust generalizability without any retraining. Using zero-shot learning, we classified disease subtypes including autosomal dominant AD and prodromal PD and clarified disease states for those with conflicting clinical information. The model also showed the ability to prioritize cognitively normal individuals at disease risk. This framework enabled the identification and quantification of continuous, individual-level disease probabilities that allow for the quantification of overlap across diseases and co-pathologies within an individual. Through this work, we establish a benchmark computational framework for enhancing diagnostic precision in NDs.
Year:
2025
APOE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), but its contribution to disease pathogenesis remains incompletely understood. Here, we integrate proteomic profiling of plasma, cerebrospinal fluid (CSF), and brain tissue from over 10,000 individuals to define the immune phenotype associated with APOE ε4. We identify a conserved, allele dose-dependent pro-inflammatory immune signature across peripheral and central tissues independent of AD diagnosis. This signature is enriched in adaptive immune cells and white matter-resident glial and vascular cells. It also emerges in patient-derived cortical organoids prior to amyloid-β and tau pathology, supporting a causal, genotype-driven mechanism. Cross-tissue comparisons reveal shared innate and antiviral responses alongside tissue-specific immune signaling. Notably, a 12-week medical ketogenic diet partially reversed the APOE ε4 immune signature. These findings position immune dysregulation as an early and tractable driver of AD risk in APOE ε4 carriers with direct implications for targeted prevention strategies.
Year:
2025
Co-pathology is a common feature of neurodegenerative diseases that complicates diagnosis, treatment and clinical management. However, sensitive, specific and scalable biomarkers for in vivo pathological diagnosis are not available for most neurodegenerative neuropathologies. Here, we present ProtAIDe-Dx, a deep joint-learning model trained on 17,187 patients and controls (Age=70.3±11.5, 53.2% of Female) that uses plasma proteomics to provide simultaneous probabilistic diagnosis across six conditions associated with dementia in aging. ProtAIDe-Dx achieves cross-validated balanced classification accuracy of 70%-95% and AUCs > 78% across all conditions. The model’s diagnostic probabilities highlighted subgroups of patients with co-pathologies, and were associated with pathology-specific biomarkers in an external memory clinic sample, even among cognitively unimpaired people. Model interpretation revealed a suite of protein networks marking shared and specific biological processes across diseases, and identified novel and previously described proteins discriminating each diagnosis. ProtAIDe-Dx significantly improved biomarker-based differential diagnosis in a memory clinic sample, pinpointing proteins leading to diagnostic decisions at an individual level. Together, this work highlights the promise of plasma proteomics to improve patient-level diagnostic work-up with a single blood draw.
Year:
2025
Collaborators (26)
Russell Swerdlow
University of Kansas Medical Center
Pau Pastor
Institut Català de la Salut
Laura Winchester
University of Oxford
Sebastian Palmqvist
Associate Professor
Lund University
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Jeffrey Dage
Senior Research Professor
Indiana University School of Medicine
Tony Wyss-Coray
Professor
Stanford University
Federica Anastasi
Senior Researcher
VU medisch centrum
Caitlin Finney
Translational Dementia Research Group Leader
Westmead Institute for Medical Research
Simon Lovestone
University of Oxford
Oskar Hansson
Full professor of Neurology
Lund University
Jeffrey Burns
University of Kansas Medical Center
Erik Johnson
Assistant Professor
Emory University School of Medicine
Niklas Mattsson-Carlgren
Professor
Lund University
Muhammad Ali
Assistant Professor
Washington University in St. Louis
Andrew Saykin
Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
Alexa Pichet Binette
Assistant professor
Université de Montréal
Carlos Cruchaga
Professor
Washington University in St. Louis
Niranjan Bose
Affiliate Associate Professor
University of Washington
Ann-Na Cho
Senior Lecturer (Tenure)
University of Sydney
Oliver Robinson
Imperial College London
Danielle van Westen
Lund University
Rik Ossenkoppele
Associate Professor in Translational Neurosience
VU Amsterdam
Lijun An
Lund University
Erik Stomrud
Lund University
Menghan Liu
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.